<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351685</url>
  </required_header>
  <id_info>
    <org_study_id>VPM1002-MN-3.05TB</org_study_id>
    <nct_id>NCT04351685</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants</brief_title>
  <acronym>VPM1002</acronym>
  <official_title>A Multicenter, Phase III, Double-blind, Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Mycobacterium Tuberculosis Infection in Newborn Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Serum Institute of India Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vakzine Projekt Management GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Serum Institute of India Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is designed as a phase III, double-blind, multicenter, randomized, single&#xD;
      administration, active-controlled, parallel-group design with two groups of newborn infants&#xD;
      receiving either VPM1002 or BCG SII (1:1 allocation) to assess the efficacy, safety and&#xD;
      immunogenicity of VPM1002 against Mtb infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is designed as a phase III, double-blind, multicenter, randomized, single&#xD;
      administration, active-controlled, parallel-group design with two groups of newborn infants&#xD;
      receiving either VPM1002 or BCG SII (1:1 allocation) to assess the efficacy, safety and&#xD;
      immunogenicity of VPM1002 against Mtb infection.&#xD;
&#xD;
      Healthy male or female newborn infants will be centrally randomized to receive the allocated&#xD;
      vaccine, stratified by the HIV status of the mother. Single dose of VPM1002 or BCG SII will&#xD;
      be administered (within 14 days of birth) strictly intradermally.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The study is designed as a double-blind study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incident cases of QFT conversion, indicating Mtb infection</measure>
    <time_frame>Minimum of 12 months and maximum of 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of TB disease in children receiving VPM1002 compared to BCG SII. Incident cases of sustained QFT conversion, indicating sustained Mtb infection.</measure>
    <time_frame>36 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6940</enrollment>
  <condition>Mycobacterium Tuberculosis Infection</condition>
  <arm_group>
    <arm_group_label>VPM1002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total 3470 subjects will be enrolled in VPM1002 arm.&#xD;
Single dose of VPM1002 will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCG SII</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Total 3470 subjects will be enrolled in BCG SII arm.&#xD;
Single dose of BCG SII will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VPM1002</intervention_name>
    <description>The active ingredient of the recombinant BCG vaccine, VPM1002 is Mycobacterium bovis A dose of 0.05 ml will be administered intradermally.&#xD;
Manufactured by the Serum Institute of India Pvt. Ltd., India&#xD;
Diluent: 1 ml of Water for injection/vial</description>
    <arm_group_label>VPM1002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG SII</intervention_name>
    <description>Commercially available BCG vaccine from Serum Institute of India Pvt. Ltd. A dose of 0.05 ml will be administered intradermally.&#xD;
Manufactured by the Serum Institute of India Pvt. Ltd., India&#xD;
Diluent: 1 ml of Sodium Chloride for injection/vial Injection</description>
    <arm_group_label>BCG SII</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A Maternal&#xD;
&#xD;
          1. Age: 18 years or older at screening.&#xD;
&#xD;
          2. Willing to comply with the trial protocol, available and willing to allow her child to&#xD;
             complete all the trial assessments and must have signed an Informed Consent form that&#xD;
             has been approved by respective Site Ethics Committee.&#xD;
&#xD;
          3. No symptoms or signs of active TB at the time of participant's enrolment.&#xD;
&#xD;
          4. Parent / guardian who intends to remain in the trial area with the child should be&#xD;
             reachable by phone during the trial period.&#xD;
&#xD;
          5. For HIV-unexposed group: Test negative for HIV within two months prior to the newborn&#xD;
             infant's vaccination. Test result must be documented, in absence of which a HIV test&#xD;
             must be performed at the infant screening visit.&#xD;
&#xD;
          6. For the HIV-exposed group: Test positive for HIV and test result must be documented.&#xD;
             If documentation is missing, a HIV test must be performed at the screening visit. The&#xD;
             newborn infant's mother must have enrolled for standard antiretroviral therapy (ART)&#xD;
             at least 2 months before the participant's birth&#xD;
&#xD;
          7. No participation in an interventional clinical trial within 3 months prior to the&#xD;
             participant's birth. In addition, if mother is breast-feeding then she must not&#xD;
             participate in another clinical trial during the current trial period while&#xD;
             breastfeeding.&#xD;
&#xD;
        B Infant&#xD;
&#xD;
          1. Healthy male or female newborn infant.&#xD;
&#xD;
          2. Birth weight of at least 2,300 g.&#xD;
&#xD;
          3. Test negative for HIV by PCR at screening if born to an HIV-infected mother.&#xD;
&#xD;
          4. No participation in an interventional clinical trial prior to enrolment. Participant&#xD;
             should not take part in another clinical trial for the duration of the current trial&#xD;
             period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A Maternal&#xD;
&#xD;
          1. Any reported or suspected substance abuse during pregnancy.&#xD;
&#xD;
          2. House-hold contact with active TB (defined as residing in the same house as an&#xD;
             individual with active TB) within the 3 months prior to enrolment.&#xD;
&#xD;
        B Infant&#xD;
&#xD;
          1. Fever at the time of enrolment.&#xD;
&#xD;
          2. Eczema or other significant skin lesion or infection at the site/s of injection as per&#xD;
             protocol.&#xD;
&#xD;
          3. Receipt of routine BCG vaccine (as per vaccination record).&#xD;
&#xD;
          4. Clinically suspected sepsis.&#xD;
&#xD;
          5. Clinically suspected sepsis.&#xD;
&#xD;
          6. Any malignant condition.&#xD;
&#xD;
          7. Any clinically significant severe congenital malformation, which may interfere with&#xD;
             the evaluation of the safety, efficacy or immunogenicity of the vaccine.&#xD;
&#xD;
          8. Concomitant treatment with medication that may significantly affect immune function&#xD;
             (e.g. systemic corticoids, immunosuppressive drugs) before trial vaccination. (Note:&#xD;
             Routine medication given at birth such as topical antibiotics for eye care and&#xD;
             vitamins A and K are permitted. In HIV-exposed newborn infants prevention of&#xD;
             mother-to-child transmission (PMTCT) based on standard of care is allowed, but must be&#xD;
             documented.)&#xD;
&#xD;
          9. Receipt of blood products or immunoglobulin before trial vaccination.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Prasad Kulkarni, MD</last_name>
    <role>Study Director</role>
    <affiliation>Serum Institute of India Pvt. Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr Prasad Kulkarni, MD</last_name>
    <phone>+ 91-20-26602384</phone>
    <email>drpsk@seruminstitute.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr Sajjad Desai, MD</last_name>
    <phone>+ 91-20-26602781</phone>
    <email>sajjad.desai@seruminstitute.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de Recherches Médicales de Lambaréné</name>
      <address>
        <city>Lambaréné</city>
        <country>Gabon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof Ayola Adegnika</last_name>
      <phone>+24106244472</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kenya Medical Research Institute / Center for Respiratory Disease Research</name>
      <address>
        <city>Nairobi</city>
        <zip>47855-00100</zip>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Videlis Nduba</last_name>
      <phone>+254724522474</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kenya Medical Research Institute - Center for Respiratory Disease Research</name>
      <address>
        <city>Siaya</city>
        <zip>144</zip>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Videlis Nduba</last_name>
      <phone>+254 724 522474</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Empilweni Services and Research Unit (ESRU)</name>
      <address>
        <city>Johannesburg</city>
        <state>Coronation Ville</state>
        <zip>2093</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof Shabir Ahmed Madhi</last_name>
      <phone>+27119834283</phone>
    </contact>
    <contact_backup>
      <last_name>Dr. Renate Strehlau</last_name>
      <phone>+27114709000</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Family Center for Research with Ubuntu</name>
      <address>
        <city>Cape Town</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof Mark Frederic Cotton</last_name>
      <phone>+27219384963</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mecru Clinical Research Unit</name>
      <address>
        <city>Medunsa</city>
        <zip>0204</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Matsontso Peter Mathebula</last_name>
      <phone>+270125215714</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Respiratory and Meningeal Pathogens Research Unit</name>
      <address>
        <city>Soweto</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof Shabir Ahmed Madhi, MD</last_name>
      <phone>+27119834283</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>South African Tuberculosis Vaccine Initiative</name>
      <address>
        <city>Worcester</city>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Angelique Kany Kany Luabeya</last_name>
      <phone>+27233465400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ifakara Health Institute</name>
      <address>
        <city>Dar Es Salaam</city>
        <zip>61665</zip>
        <country>Tanzania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Francis Mhimbira</last_name>
      <phone>+225754291657</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Research Council / Uganda Virus Research Institute and London School of Hygiene and Tropical Medicines (MRC/UVRI and LSHTM) Uganda Research Unit</name>
      <address>
        <city>Entebbe</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Anne Wajja</last_name>
      <phone>+256778103960</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Makerere University/CISMAC</name>
      <address>
        <city>Kampala</city>
        <zip>7062</zip>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Victoria Nankabirwa</last_name>
      <phone>+256755757460</phone>
    </contact>
  </location>
  <location_countries>
    <country>Gabon</country>
    <country>Kenya</country>
    <country>South Africa</country>
    <country>Tanzania</country>
    <country>Uganda</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bacterial and fungal diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

